StockData
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. (CCCC) stock

CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.53−0.12 (-4.53%)

Close on Nov 17, 2026Market cap $311.25MP/E –Yield –

C4 Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

C4 Therapeutics's total debt was $0 at Dec 31, 2023. For fiscal 2023 it was $0, down 100.0% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$11.48M+6.6%
FY2021Dec 31, 2021$10.77M+7.1%
FY2020Dec 31, 2020$10.05M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$10.34M-7.1%
Q1 FY2023Mar 31, 2023$10.91M-0.3%
Q4 FY2022Dec 31, 2022$11.48M+6.6%
Q3 FY2022Sep 30, 2022$11.30M+6.7%
Q2 FY2022Jun 30, 2022$11.12M+6.8%
Q1 FY2022Mar 31, 2022$10.94M+7.0%
Q4 FY2021Dec 31, 2021$10.77M+7.1%
Q3 FY2021Sep 30, 2021$10.59M+7.2%
Q2 FY2021Jun 30, 2021$10.41M–
Q1 FY2021Mar 31, 2021$10.23M–
Q4 FY2020Dec 31, 2020$10.05M–
Q3 FY2020Sep 30, 2020$9.88M–

More C4 Therapeutics figures

See a number that looks wrong?